ad image

Company Info

Merck & Co.

Merck & Co.

Drug Discovery & Development

Overview

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. 
Merck & Co.
Contributions
31 Contributions1 / 2
Merck & Co.
M&A

Merck to Acquire VelosBio

Merck & Co.

PR-M11-20-010-1197Nov 11, 2020
Merck & Co.
Vaccine

Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating Pneumococcal Conjugate Vaccine

Merck & Co.

PA1299Sep 11, 2020
Merck & Co.
COVID-19 Vaccine

IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2

Merck & Co.

PR-M05-20-NI-036May 26, 2020
Merck & Co.
M&A

Merck to Acquire Themis

Merck & Co.

PR-M05-20-NI-035May 26, 2020
Merck & Co.
Emergency Response

Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response

Merck & Co.

PR-M04-20-NI-008Apr 07, 2020
Merck & Co.
Drug Development

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Merck & Co.

PR-M01-20-NI-003Jan 02, 2020
Merck & Co.
M&A

Merck to Acquire ArQule, Advancing Leadership in Oncology

Merck & Co.

PR-M12-19-NI-017Dec 12, 2019
Merck & Co.
Vaccine Approval

Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

Merck & Co.

PR-M11-19-NI-011Nov 13, 2019
Merck & Co.
Vaccine

CDC Advisory Recommends Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26

Merck & Co.

PR-M07-19-NI-004Jul 01, 2019
Merck & Co.
Track and Trace

IBM, KPMG, Merck and Walmart to Collaborate as Part of FDA’s Program to Evaluate the Use of Blockchain to Protect Pharmaceutical Product Integrity

Merck & Co.

PR-M06-19-NI-021Jun 17, 2019
Merck & Co.
M&A

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

Merck & Co.

PR-M05-19-NI-067May 23, 2019
Merck & Co.
Trial Update

Merck Provides Update on Phase 3 KEYNOTE-062 Trial

Merck & Co.

PR-M04-19-NI-085Apr 29, 2019
Merck & Co.
Granted Designation

Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

Merck & Co.

PR-M08-18-NI-037Aug 10, 2018
Merck & Co.
EMA

European Medicines Agency Adopts Positive Opinion for KEYTRUDA®(pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy

Merck & Co.

PR-M08-18-NI-009Aug 02, 2018
Merck & Co.
Approval

Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Euthyrox®

Merck & Co.

PR-M07-18-NI-099Jul 30, 2018
Merck & Co.
Therapy Approval

KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Merck & Co.

PR-M07-18-NI-098Jul 30, 2018
Merck & Co.
Phase III Trial

KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial

Merck & Co.

PR-M07-18-NI-093Jul 27, 2018
Merck & Co.
HIV Therapy

Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine

Merck & Co.

PR-M07-18-NI-083Jul 25, 2018
Merck & Co.
Collaboration

Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection

Merck & Co.

PR-M06-18-NI-015Jun 05, 2018
Merck & Co.

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival for Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck & Co.

PR-M05-18-NI-097May 25, 2018
1 / 2
0 Contributors1 / 0

No authors found

1 / 0